NCT06792591

Brief Summary

Investigate the accuracy of PEM in detection of breast cancer.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
54

participants targeted

Target at P25-P50 for all trials

Timeline
6mo left

Started Feb 2025

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress72%
Feb 2025Nov 2026

First Submitted

Initial submission to the registry

January 20, 2025

Completed
4 days until next milestone

First Posted

Study publicly available on registry

January 24, 2025

Completed
8 days until next milestone

Study Start

First participant enrolled

February 1, 2025

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2026

Expected
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2026

Last Updated

January 24, 2025

Status Verified

January 1, 2025

Enrollment Period

1.6 years

First QC Date

January 20, 2025

Last Update Submit

January 20, 2025

Conditions

Breast Cancer

Outcome Measures

Primary Outcomes (1)

  • Diagnostic performance of positron emission mammography in breast cancer

    Investigate PEM as non invasive method for early detection of breast cancer

    Base line

Interventions

PEMDEVICE

Accuracy of PEM in detection of breast cancer

Eligibility Criteria

Age18 Years - 80 Years
Sexfemale
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients suspected with breast cancer or pathological proven to have breast cancer, patients underwent breast mammography or breast US and suspected to have breast cancer.

You may qualify if:

  • patients suspected with breast cancer.

You may not qualify if:

  • patient with glucose level \>200 mg/dl.
  • Pregnant patients

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Breast Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Central Study Contacts

Zainab Fathy Mohammad

CONTACT

+20 01099024404zainab.fathy.95@gmail.com

Maha Khalil Mahmoud

CONTACT

+20 10 04037100mahakhalil12@yahoo.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
AssiutU

Study Record Dates

First Submitted

January 20, 2025

First Posted

January 24, 2025

Study Start

February 1, 2025

Primary Completion (Estimated)

September 1, 2026

Study Completion (Estimated)

November 1, 2026

Last Updated

January 24, 2025

Record last verified: 2025-01